FDA puts Catabasis' DMD therapy on Fast Track

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $1.24 (10%) to $13.64 Monday after FDA granted Fast Track designation to CAT-1004 to treat Duchenne muscular dystrophy. The company began a Phase I/II trial last month of the conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B ( NF-kB). ...